aXichem AB (publ), (aXichem), a developer of industrial feed and supplement ingredients,announces that the board of directors, in its annual revision of the company's communication policy, has decided that from now on aXichem shall not publish any financial forecasts or forecast-like targets.
“aXichem is in a growth phase, which can mean large fluctuations in sales between reporting periods. Our assessment is therefore that we can more effectively communicate aXichem's commercial development by, in addition to the accounting in the company's financial reports, continuously informing about the exciting development we see regarding the interest in the company's product offering as an ingredient in dietary supplements and as an additive in animal feed. The board's decision means that the company's total sales are presented in the quarterly reports and previously communicated sales targets will not be commented on,” says Jan Gustavsson, chairman of the board of aXichem.
This information is such that aXichem is obliged to make public according to the EU's market abuse regulation (EU no. 596/2014). The information was submitted, through the provision of the specified contact person, for publication on 27 August 2024, 08:15 AM CET.
Company contact: Torsten Helsing, CEO, aXichem AB
Phone: +46 706 863 355 Email: torsten.helsing@axichem.com
About aXichem aXichem develops, patents and markets natural analogue industrial chemicals, i.e., synthetically produced substances that have similar and comparable properties to natural substances. The company's first product is phenylcapsaicin, which the company commercializes under two brands, aXiphen® and aXivite®, as an ingredient in animal feed and dietary supplements, respectively. The business is divided into three market areas with different applications for phenylcapsaicin: as an ingredient in feed for poultry, such as chicken and turkey; as an ingredient in food supplements for gut health, weight control and sports and exercise; and as an ingredient in food supplements for the bio- enhancement of curcumin and melatonin. aXichem is listed on the Nasdaq First North Growth Market. Certified advisor for aXichem is Västra Hamnen Corporate Finance AB.
